Molzym Gets CE Mark for Sepsis PCR Test | GenomeWeb
NEW YORK (GenomeWeb News) – German firm Molzym has received the CE Mark for its PCR-based test for sepsis enabling the firm to market the test throughout the European Union.
 
Molzym’s SepsiTest detects more than 345 relevant sepsis pathogens and can provide results in less than four hours. The firm claims that it is the first PCR-based assay that can detect all of the relevant strains in one test.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.